Sean Porazinski

Abstract 751: A workflow integrating multi-omics with patient-specific 3D cell models for interrogating precision medicine approaches in clinically-relevant timeframes.

Elahe Minaei, Stella Davy, Ali McCorkindale, Peilin Tian et autres

au (code pays fourni par la source)

Abstract 769: Matrix mechanics modulate cancer cell plasticity and drug responses.

Chantal Kopecky, Elvis Pandžić, Morgan Hamon, Sean Porazinski et autres

au (code pays fourni par la source)

Abstract 4398: Developing 3D cell models for high-throughput antibody-drug conjugate screening in cancer

Peilin Tian, Morgan Hamon, Sean Porazinski, Maria Kavallaris et autres

au (code pays fourni par la source)

Abstract 4918: Bioprinted multicellular microenvironments to accelerate immunotherapy discovery in pancreatic cancer

Aji Istadi, Ali McCorkindale, Silvia Lombardi, Inna Navarro et autres

au (code pays fourni par la source)

Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres

Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Patrick Bergsma, Sean Porazinski, Aji Istadi, Diego Chacon Fajardo et autres